Efferon
PrivateLast Round
Seed
Nov 10, 2026
Total Funding Raised
$4.64M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Efferon operates in Healthcare & Life Sciences and is based in Tallinn. Its latest recorded funding round was a Seed round in November 2026.
Efferon is a therapeutic devices company that develops and manufactures advanced therapeutic devices for the treatment of sepsis and multiple organ failure syndrome through innovative extracorporeal blood purification technologies.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Efferon Comparables
Compare Efferon with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alteco Medical AB | 89% | |
| ExThera Medical | 86% | |
| Aferetica S.r.l. | 84% |
For institutional investors. Book with your work email.
Efferon Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 10, 2026 | ||||
| Series A | Jun 3, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$4.64M raised in Seed round
- Jun 3, 2026
$3M raised in Seed round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 10, 2026
Efferon GmbH receives $4.8M from existing private investors in the DACH region to support commercial expansion in Europe, India, and Latin America, regulatory work, distributor development, and clinical evidence.
- attends_eventOct 21, 2026
Efferon GmbH joins clinicians and partners worldwide at the 39th ESICM Annual Congress in Portugal to discuss how hemoadsorption can go beyond endotoxin in sepsis treatment.
- attends_eventOct 11, 2026
Efferon GmbH earns a spot in the Battlefield 200 showcase at TechCrunch Disrupt 2026, placing it among the world's most promising early-stage startups.
- partners_withOct 5, 2026
Efferon GmbH partners with Helmier Private Limited to make Efferon available as a registered medical device for hospitals and intensive care teams across India on Oct 5th '26.
For institutional investors. Book with your work email.
Efferon Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Efferon's valuation, stock price, and market status.
Is Efferon a public or private company?
Efferon is a private company.
What is the current stock price of Efferon?
Efferon is a private company, so its shares have no public market price. Caplight tracks Efferon's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Efferon worth (valuation)?
Valuation information for Efferon is not publicly available.
Can I buy Efferon stock?
Efferon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Efferon's last funding round?
Efferon's most recent funding round was Seed on November 10, 2026.
Who are the main investors in Efferon?
Investor information for Efferon is not publicly disclosed.
Will Efferon IPO soon?
No public IPO plans have been announced for Efferon.
How can I track Efferon secondary market activity?
Caplight tracks bids, offers, and trades in Efferon's shares on secondary markets.